Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab and chemotherapy in Ph- BCP ALL
NCT03367299Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Jun 2018
- Primary completion
- Sep 2024
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by GIMEMA. Started Jun 2018; status: completed.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03367299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03367299.